We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

X-ray Crystallography Study May Lead to New Drugs to Block Cancer Metastasis

By LabMedica International staff writers
Posted on 28 Apr 2016
Cancer researchers expect that the structure of the enzyme P-Rex1 (PIP3-dependent Rac exchanger 1), which was recently established by X-ray crystallography, will lead to development of a new generation of cancer chemotherapeutic agents to block the processes leading to metastasis.

P-Rex1 is a Rho guanine nucleotide exchange factor synergistically activated by the lipid PIP3 (phosphatidylinositol 3,4,5-trisphosphate) that plays an important role in the metastasis of breast, prostate, and skin cancer, which makes it an attractive therapeutic target. However, the molecular mechanisms behind P-Rex1 regulation have been poorly understood.

Investigators at the University of Michigan (Ann Arbor, USA) used X-ray crystallography to determine structures of the P-Rex1 pleckstrin homology domain (a protein domain of approximately 120 amino acids that occurs in a wide range of proteins involved in intracellular signaling) bound to the headgroup of PIP3.

They reported in the April 14, 2016, online edition of the journal Structure that PIP3 binding to the pleckstrin homology domain was required for P-Rex1 activity in cells but not for membrane localization, which pointed to an allosteric activation mechanism by PIP3.

"P-Rex1 has been an attractive drug target for some time," said senior author Dr. John J.G. Tesmer, professor of pharmacology and biological chemistry at the University of Michigan. "But development of these drugs has been hindered by a lack of understanding of its structure and regulatory mechanisms. Our data have confirmed the location of the binding site, which will greatly assist with the identification or design of small molecules that target this mechanism of activation."

Related Links:
University of Michigan

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more